Structural and Functional Assessment in Patients Treated with Systemic Isotretinoin Using Optical Coherence Tomography and Frequency-Doubling Technology Perimetry

Basit Öğe Kaydı
dc.contributor.authorBakbak, Berker
dc.contributor.authorGedik, Sansal
dc.contributor.authorKoktekir, Bengu Ekinci
dc.contributor.authorGuzel, Huseyin
dc.contributor.authorAltinyazar, Hilmi Cevdet
dc.date.accessioned2020-03-26T18:43:31Z
dc.date.available2020-03-26T18:43:31Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractA causal association between central nervous system neuropathy and oral isotretinoin has been reported. In this study we aimed to assess retinal nerve fibre layer (RNFL) thickness and visual field changes in patients treated with systemic isotretinoin. Thirty-nine patients treated with 1 mg/kg daily oral isotretinoin were enrolled in this prospective clinical trial. All patients underwent complete ophthalmologic assessment before treatment, on day 60, and 3 months after completion of treatment. RNFL thickness measurements were performed with Stratus optical coherence tomography. Functional testing included frequency-doubling technology perimetry and Humphrey field analyser. Main outcome measures were average RNFL thicknesses and visual field indices (mean deviation, pattern standard deviation). Measurements of RNFL thickness showed no statistically significant change between the three measurements (p = 0.180). No statistically significant differences were observed in the frequency-doubling technology indices (mean deviation and pattern standard deviation, p = 0.066 and p = 0.103, respectively) and in the Humphrey field analyser indices (mean deviation and pattern standard deviation, p = 0.091 and p = 0.087, respectively) at day 60 of treatment or 3 months after the cessation of treatment. In this study of 39 patients, systemic use of isotretinoin (1 mg/kg daily) does not cause a statistically significant change in peripapillary RNFL thickness or visual field findings within the usage period, and within 3 months after cessation.en_US
dc.identifier.doi10.3109/01658107.2013.792357en_US
dc.identifier.endpage103en_US
dc.identifier.issn0165-8107en_US
dc.identifier.issue3en_US
dc.identifier.pmid28163763en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage100en_US
dc.identifier.urihttps://dx.doi.org/10.3109/01658107.2013.792357
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29844
dc.identifier.volume37en_US
dc.identifier.wosWOS:000319756700002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherINFORMA HEALTHCAREen_US
dc.relation.ispartofNEURO-OPHTHALMOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdverse effecten_US
dc.subjectfrequency-doubling technologyen_US
dc.subjectisotretinoinen_US
dc.subjectoptic nerveen_US
dc.subjectvisual fielden_US
dc.titleStructural and Functional Assessment in Patients Treated with Systemic Isotretinoin Using Optical Coherence Tomography and Frequency-Doubling Technology Perimetryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu